tremelimumab   Click here for help

GtoPdb Ligand ID: 8462

Synonyms: CP-675 | CP-675,206 | CP-675206 | ticilimumab
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tremelimumab is a fully human investigational monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4, CD152). Tremelimumab was designed as an antineoplastic agent. A BLAST sequence alignment matches tremelimumab to patent US 6682736, and identifies antibody clone 11.2.1 [2].
Click here for help
Bioactivity Comments
Data for two antibody clones measured by competition ELISAs are provided in US 6682736 [2]. Clones 4.1.1. and 11.2.1 inhibit binding of CD80 and CD86 to CTLA4 with almost identical IC50 values. The affinity for direct binding between antibody and CTLA4 is only provided for subclone 4.1.1.1 in this patent.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
cytotoxic T-lymphocyte-associated protein 4 (CD152) Primary target of this compound Hs Antibody Binding 8.9 pKd - 2
pKd 8.9 (Kd 1.24x10-9 M) [2]
Description: Average Kd from associated patent, for a competition ELISA assessing binding of the antibody to CTLA4.